Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Filip Krag Knop, Vanita R. Aroda, Ruben Duque do Vale, Thomas Holst‐Hansen, Peter Nørkjær Laursen, Julio Rosenstock, Domenica Rubino, William Timothy Garvey
The abstract is not reproduced here because its license does not permit redistribution. Read it at the original source.
Record
- Archive ID
- doi:10.1016/s0140-6736(23)01185-6
- Published
- Jun 25, 2023
- Venue
- The Lancet
- DOI
- 10.1016/s0140-6736(23)01185-6
- PubMed
- 37385278
- Categories
- Pharmacology and Obesity Treatment
- Provenance
- openalex